Dublin, March 17, 2025 (GLOBE NEWSWIRE) — The “Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players” report has been added to ResearchAndMarkets.com’s offering.
The global anti-obesity drugs market size is estimated to grow from USD 12.8 billion in the current year to USD 104.9 billion by 2035, at a CAGR of 21.1% during the forecast period, till 2035.
According to the World Health Organization, obesity is the fifth-leading cause of mortality worldwide. In order to curb this growing concern, various medications are currently available in the market or are being investigated across different phases of development.
Anti-obesity drugs, also referred to as weight loss drugs, include several pharmaceutical treatments designed specifically to assist individuals aiming to manage obesity and treat associated concerns, such as diabetes mellitus and cardiovascular disorders. These drugs work through several mechanisms, including appetite suppression, inhibition of fat absorption, and enhancement of metabolic rate. The selection of appropriate anti-obesity drugs is tailored to each patient’s profile, taking into account their co-morbidities and potential risks to metabolic functions, as determined by healthcare professionals. Additionally, the development of novel compounds coupled with ongoing advancements in drug formulation and delivery systems, have led to the emergence of more effective and safer anti-obesity medications.
With rising global obesity rates and increased awareness of the associated health risks including diabetes, cardiovascular diseases, and certain cancers, the demand for effective anti-obesity drugs has surged. Moreover, with a growing emphasis on long-term management of obesity, the anti-obesity drugs market is poised to grow significantly, thus offering significant opportunities to stakeholders in the coming years.
Anti-Obesity Drugs Market: Key Insights
The report delves into the current state of the anti-obesity market and identifies potential growth opportunities within the industry. The key takeaways of the report are:
- Currently, close to 225 drugs are marketed / being developed for the management of obesity; around 50% of these can be administered through oral route
- A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; majority of these partnerships (~30%) were research and development agreements
- The growing awareness among patients about the health risks, associated with obesity coupled with its increasing prevalence, is driving the anti-obesity market and positioning it for steady growth in the foreseeable future
- The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035
- Currently, the centrally acting anti-obesity drugs dominate the market; notably, parenteral route of administration is expected to capture the majority share (~85%) in market by 2035
{INFOGRAPHIC_PLACEHOLDER}
Anti-Obesity Drugs Market: Key Segments
Small Molecules is the Fastest Growing Segment of the Anti-obesity Drugs Market
- Based on the type of molecule, the global market for anti-obesity is segmented into biologics and small molecules. Currently, the small molecules segment occupies the highest share in the overall market. However, the landscape is likely to evolve as biologics emerge as a promising and more effective alternative that can target the underlying biological pathways associated with obesity.
Semaglutide is Likely to Hold the Largest Share of the Anti-obesity Drugs Market During the Forecast Period
- Based on the active compound used, the global market for anti-obesity is segmented into Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide, and other active compounds.Currently, Semaglutide leads the anti-obesity drugs market, and this can be attributed to its strong efficacy in weight management and diabetes control. However, owing to significant research progress, tirzepatide has gained attention for its dual action as both a GLP-1 and GIP receptor agonist, demonstrating superior weight loss results in clinical trials.
Anti-Obesity Drugs Market for GLP-1 agonist is Likely to Grow at a Relatively Faster Pace During the Forecast Period
- Based on the mechanism of action, the global market for anti-obesity is segmented across GLP-1 agonist / GIP agonist, GLP-1 agonist / GCGR agonist, GLP-1 agonist, GLP-1 agonist / amylin analogue, GLP-1 / GCGR / GIP agonist and other mechanisms of action. Presently, the market is dominated by GLP-1 agonists, due to their ability to mimic hormone glucagon-like peptide 1 (GLP-1), thereby promoting significant weight loss.
Anti-Obesity Drugs Market for Single Agonist is Likely to Grow at a Higher CAGR During the Forecast Period
- Based on the type of agonist, the global market for anti-obesity is segmented into single-agonist, dual-agonist and tri-agonist. Currently, single agonist captures the maximum anti-obesity drugs market share owing to its user-friendliness for facilitating patient adherence.
Anti-Obesity Drugs Catering to Centrally Acting Pathways is Likely to Dominate the Anti-Obesity Drugs Market During the Forecast Period
- Based on the action pathway, the global market for anti-obesity is distributed across centrally acting, peripherally acting and, centrally and peripherally acting pathways. Presently, centrally acting segment captures the highest anti-obesity drugs market share and is expected to dominate the market during the forecast period. It is important to note that despite ongoing research into alternative pathways, robust clinical evidence supporting the efficacy of centrally acting agents ensures their continued dominance in the market.
Parenteral Route Hold the Largest Share of the Anti-Obesity Drugs Market
- Based on the routes of administration, the global market for anti-obesity is segmented into oral and parenteral. Currently, the parenteral route captures the majority share of the market, owing to its rapid onset of action and higher bioavailability compared to oral formulations.
North America Accounts for the Largest Share of the Market
- Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America. In the current scenario, North America is likely to capture the largest market share. This can be attributed to a high prevalence of obesity and related comorbidities, driving the demand for effective treatment options. Additionally, the region benefits from advanced healthcare infrastructure, significant investment in pharmaceutical research, and robust regulatory frameworks that facilitate the development and approval of new therapies.
{INFOGRAPHIC_PLACEHOLDER}
Anti-Obesity Drugs Market: Research Coverage
The report on anti-obesity drugs market features insights on various sections, including:
- Market Sizing and Opportunity Analysis: An in-depth analysis of current market opportunity and the future growth potential of anti-obesity drugs market, focusing on key market segments, including type of molecule, active compound used, mechanism of action, type of agonist, action pathway, route of administration, and geographical regions.
- Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.
- Market Landscape: A comprehensive evaluation of companies engaged in anti-obesity domain, based on several relevant parameters, such as stage of development, type of molecule, mechanism of action, type of agonist, route of administration, dosage frequency, and type of therapy.
- Anti-obesity Drug Developer Landscape: The report features a list of players engaged in the anti-obesity drug domain, along with analyses based on year of establishment, company size, and location of headquarters, and most active players.
- Company Profiles: In-depth profiles of key industry players in the anti-obesity drug domain, featuring information on company overview, financial information (if available), metaverse in healthcare portfolio, recent developments, and future outlook statements.
- Big Pharma Players: An insightful review of various anti-obesity initiatives undertaken by big pharma players, highlighting trends across various parameters, such as year of initiative, type of initiative, number of partnerships, type of partnership, and type of expansion.
Key Questions Answered in this Report
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
The opportunity for anti-obesity drugs market has been distributed across the following segments:
Type of Molecule
Active Compound Used
- Tirzepatide
- Semaglutide
- Retatrutide
- Survodutide
- Cagrilintide and Semaglutide
- Orforglipron
- Liraglutide
- Other Active Compounds
Mechanism of Action
- GLP-1 Agonist / GIP Agonist
- GLP-1 Agonist / GCGR Agonist
- GLP-1 Agonist
- GLP-1 Agonist / Amylin Analogue
- GLP-1 / GCGR / GIP Agonist
- Other Mechanisms of Action
Type of Agonist
- Single-Agonist
- Dual-Agonist
- Tri-Agonist
Action Pathway
- Centrally Acting
- Peripherally Acting
- Centrally Acting and Peripherally Acting
Route of Administration
Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
Sales Forecast
- Contrave / Mysimba
- Feisumei
- Imcivree
- LOMAIRA
- QSYMIA
- Saxenda
- Wegovy / Ozempic
- Zepbound / Mounjaro
- BI 456906
- CagriSema
- HM11260C
- HRS-9531
- IBI362
- LM-008
- LY3437943
- LY3502970
- TG103
- Semaglutide 7.2 mg (Subcutaneous)
- Semaglutide (Oral)
- XW003
Key Players Profiled:
- Eli Lilly
- Pfizer
- Regeneron
- Kallyope
- CinFina Pharma
- Viking Therapeutics
- AstraZeneca
- Novo Nordisk
- Roche
- Adocia
- Boehringer Ingelheim
- Zealand Pharma
- Hanmi Pharm
- Jiangsu Hengrui Pharmaceuticals
- Gmax Biopharma
- PegBio
- QL Biopharm
- Sciwind Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/9sg738
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
